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To the Editor: Marfan syndrome (MFS) (MIM 154700) is a heri-
table disorder of connective tissue characterised by excessive 
height and limb length disproportion, together with ocular, 
cardiovascular and skeletal manifestations.  The condition is an 
autosomal dominant trait, and can be transmitted from genera-
tion to generation with variable severity.  The determinant gene 
FBN1 is situated at the chromosomal locus 15q21.1 and codes 
for the protein fibrillin-1.1
Since 1972 more than 160 persons with a provisional 
diagnosis of MFS have been referred to the genetic clinic 
at Groote Schuur Hospital, University of Cape Town. The 
condition is present in all population groups and there is 
no obvious predilection for any particular community.2 The 
frequency of MFS in the USA is quoted as 1 in 5 000. If this 
figure is extrapolated to South Africa, it can be estimated that 
there could be 10 000 affected persons in this country.
Genetic counselling and appropriate medical management 
of MFS are dependent on diagnostic precision, which can be 
a difficult matter.  Indeed, many persons with a marfanoid 
habitus have the less severe MVP (mitral valve prolapse)3 
or MASS (mitral valve, aortic root dilation, skeletal, skin) 
syndromes.4 Moreover, it is uncertain whether or not the 
accepted diagnostic criteria for MFS are applicable to all 
populations in South Africa.  Molecular investigations would 
go a long way towards resolving these problems, but in terms 
of local health priorities and economic constraints, it is not 
possible to offer routine molecular diagnostic laboratory 
services.  In a pilot study to address this issue we investigated 
DNA specimens from 9 South Africans with a clinical diagnosis 
of possible MFS.  In order to confirm the validity of the 
molecular screening programme in the local context, some of 
these persons met the full diagnostic criteria for MFS, while 
others represented the MVP-MASS spectrum.
Methods
Mutation analysis was undertaken at St George’s Hospital 
Medical School, London, on DNA specimens from 9 
South Africans with a provisional diagnosis of MFS, using 
conventional techniques.5 The polymerase chain reaction 
(PCR), denaturing high-performance liquid chromatography 
(dHPLC) analysis and direct sequencing were carried out in 
order to perform mutation screening involving 65 exons in the 
FBN1 gene.
Results
Both positive and negative results were obtained; these have 
important implications for the affected South Africans and 
their families.  Brief case reports are provided in order to give 
perspective on the practical issues involved, to demonstrate 
the diagnostic value of this test, and to explore the feasibility of 
molecular testing for MFS in South Africa.
Case reports
Patient 1
Patient 1 was a member of a large South African family of 
Indian stock.  Clinically, she had severe manifestations of MFS 
– she was tall, with limb length disproportion and marked 
arachnodactyly.  Her eyes were normal.  Dilatation of the 
root of the aorta and incompetence of the aortic valve led 
to her final hospital admission. She died suddenly in 1989 
at the age of 42 years, following cardiac surgery. Her eldest 
son was found to have the characteristic Marfanoid habitus, 
and a slightly increased aortic root diameter of 3.9 cm (upper 
normal limit 3.8 cm) at the age of 20 years; a total of 12 family 
members in 3 generations had been previously examined 
clinically and deemed to be affected.
A heterozygote substitution of nucleotide 7713 from T to A 
in exon 62 of the FBN1 gene was identified.  This previously 
unreported mutation introduces a premature termination 
codon in place of a cysteine (C2571X) and it could lead to 
a truncated protein encoded by the gene, with disruptive 
consequences for the protein structure.
The family members, who are widely dispersed throughout 
South Africa, will be contacted and genetic counselling will be 
offered.  The cascade screening technique will be employed 
and close co-operation with cardiological colleagues will 
be maintained.  Thereafter, following this feasibility study, 
diagnostic confirmation will be undertaken using a molecular 
probe for the specific mutation, using buccal cheek swabs, 
sputum, or DNA obtained from venous blood specimens.
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The second patient, a boy of mixed Cape ancestry, was fostered 
at an early age and no family history was available.  He had 
a marfanoid habitus, bilateral dislocated lenses and mitral 
valve prolapse. DNA investigations revealed a heterozygous 
substitution of nucleotide 6749 from A to G in exon 55 which 
is predicted to affect the cbEGF-like domain number 35 of 
the fibrillin-1 protein.  This previously unreported mutation 
affects one of the amino acids that are invariable in this type 
of domain throughout the protein (E2250G). The finding 
is consistent with a causative mutation that could result in 
disruption of the fibrillin-1 protein structure.
The mutation confirms the diagnosis of MFS, and provides 
a basis for rational management and for prenatal or postnatal 
diagnosis of any of his future offspring who have a 50:50 
chance of inheriting the mutation.
Patient 3
This boy of mixed Cape ancestry, born in 2002, had severe 
manifestations of MFS including classic skeletal features, gross 
myopia, and mitral regurgitation that necessitated repair by 
the age of 3 years. Joint contractures present at birth improved 
with time and had resolved at the age of 3. The differential 
diagnosis was either severe neonatal MFS, or Beals syndrome.
A mutation found in exon 32 consisted of a heterozygote 
substitution from G to T at position –1 in the flanking region 
of exon 32, occurring at a site classically involved in exon 
splicing. This mutation has not been identified previously, and 
it is believed to be causative since it could produce an altered 
protein by changing the reading frame and resulting in a 
truncated protein.  This finding confirms the diagnosis of MFS 
and facilitates prognostication and management decisions.
Patients 4 - 9
In one patient, DNA extracted from a histological specimen in a 
paraffin block from a deceased relative proved to be technically 
inadequate.  No mutation in the fibrillin-1 gene was detected in 
the DNA of 5 other patients.  One of these individuals had the 
classical features of MFS and a positive family history; further 
molecular studies will be undertaken.  The remaining 4 all had 
the MVP or MASS phenotype rather than the classic MFS; the 
negative results provided further reassurance concerning the 
long-term prognosis and appropriate medical management.
Discussion
In the MFS screening clinic at St George’s Hospital, London, 
only 4 of 10 referred patients actually have MFS. The others 
have an uncomplicated non-syndromic marfanoid habitus, 
or ‘overlap’ conditions in the MVP/MASS spectrum.  A very 
small minority have specific genetic disorders such as the 
Beals syndrome (congenital contractural arachnodactyly (MIM 
121050)) or the Shprintzen-Goldberg syndrome (MIM 182212). 
The experience at the Genetic Clinic at Groote Schuur Hospital, 
Cape Town is very similar.2
A firm diagnosis of MFS has important implications for 
management and prognosis.  These can include lifelong 
antihypertensive therapy to reduce the force of the cardiac 
impulse, and regular surveillance of the aortic root, heart, 
eyes and skeleton.  Major surgery may be necessary for 
aortic or valvular incompetence, and there is a significant 
risk of potentially lethal dissection of the aorta in adulthood. 
Genetically, an affected person has an even chance of 
transmitting the disorder to each of his or her offspring.
In contrast to MFS, the marfanoid habitus-MASS-MVP group 
of conditions are comparatively benign, and compatible with a 
normal lifestyle.  It therefore follows that diagnostic precision 
is crucial and that both positive and negative molecular 
findings are of considerable benefit to affected persons and 
their families.
In Europe, a full-scale genetic and molecular service for 
individuals and families with MFS is now available.6 The cost 
of the initial mutation analysis for each affected individual is 
approximately R10 000 in South African currency.  Once the 
specific mutation has been identified, focused testing in other 
family members is substantially cheaper (R1 500). Tracing 
family members and providing appropriate genetic counselling 
and medical management can be a major undertaking; 
in Europe these activities are carried out by networked 
medical genetic facilities, and all costs are met from national 
governmental resources.  In view of the serious complications 
that can occur in MFS this expensive service is cost-effective.
In South Africa it is predicted that there are more than  
10 000 people with MFS, and many more with the marfanoid 
habitus-MVP-MASS spectrum of disorders.  These individuals 
and their families would benefit from molecular screening and 
as demonstrated in this pilot project, this approach is feasible.  
The technology is available or could be developed in this 
country and the existing personnel and infrastructure could 
be expanded in order to deliver a molecular testing service 
of this type.  In the first instance, cascade screening, genetic 
counselling and molecular testing will be undertaken in the 
large South African family in which a unique mutation has 
been detected.
The fact that the MFS gene is large and that most affected 
families are unique with regard to their own mutation has 
been used as an argument against routine molecular genetic 
screening.  It has been suggested that simple techniques 
such as clinical examination, ophthalmological assessment 
and echocardiography would be adequate for the diagnostic 
categorisation of potentially affected individuals in a family 
with MFS. This approach has largely been superseded by 
molecular technology in Europe and the USA, but it may still 
be appropriate in a developing country such as South Africa.  
It is relevant, however, that screening of this type would 
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cost about R1 500 and would have to be repeated at regular 
intervals.  Conversely, molecular diagnosis, with an initial cost 
of about R10 000 would be definitive in a family where the 
mutation was detected, and would not need to be repeated in 
the affected persons.  In this way savings would be made since 
annual echocardiograms would not be necessary for those 
shown to be unaffected.
In the final analysis, the diagnostic screening procedures 
undertaken will probably depend on personal and national 
priorities for the allocation of available resources. 
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